~~<i id='A99F3D00E7'><strike id='A99F3D00E7'><tt id='A99F3D00E7'><pre id='A99F3D00E7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

fashion

author：hotspot 2025-10-01 15:30:04 - browse：97

The FDA building -- First Opinion coverage from STAT — Adobe

WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives.

Richard Pazdur, director of the FDA Oncology Center of Excellence, hates bureaucracy. It stifles his ideas for getting treatments to cancer patients faster — of which there are many.

To cut through that bureaucracy, Pazdur has a trick: “Don’t tell anybody,” he said to laughter at a meeting of the advocacy group Friends of Cancer Research Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Russia's threat to pull out of Ukraine grain deal raises fears about global food security

knowledge

hotspot

focus

hotspot

explore

AdobePfizerandModernaaren’ttheonlyvaccinemoney-makers.MuchoftherevenueandprofitsfromCovid-19vaccines

WSS

Mark Cuban is blaming the wrong people for high drug costs

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

Superbugs, antibiotic resistance get scrutiny in congress

Novo Nordisk touts Wegovy study, but still struggling with supply

Superbugs, antibiotic resistance get scrutiny in congress

Health AI: on the border between health care and tech

entertainment

fashion

knowledge

Continuity nursing helped my family in our darkest PICU moments

Companies helping big Covid

Cancer drug shortages should be causing more outrage

After half a century, Israel moves to evict squatter from his cave home on the beach

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Treatments for cramps don't cut it. Why aren't there better options?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Aspartame and sugar

Duchenne breakthrough therapy leaves behind pioneering families

Superbugs, antibiotic resistance get scrutiny in congress

hotspot

Judge sides with young activists in first

Superbugs, antibiotic resistance get scrutiny in congress

What to know about the judge who will handle the Trump case

Illinois Supreme Court finds assault weapons ban constitutional

Novo Nordisk touts Wegovy study, but still struggling with supply

Antibody drugs appear effective. Now can we make enough of them?

focus

focus

hotspot

explore